Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

Author's Avatar
Jul 06, 2021

Creating transformative therapeutics for immune diseases by combining InveniAI's validated AI-based platform, AlphaMeld®, with Sosei Heptares' GPCR Structure-based Drug Design and early development capabilities

Focus on identifying GPCR targets across multiple disease areas

PR Newswire